Delays in Core Laboratory Testing, Wednesday, January 11, 2017

On Wednesday, January 11, 2017, instrumentation in the core clinical laboratory will be undergoing required maintenance from approximately 09:30 – 15:00.  This will delay the resulting of the following assays in that time window:

Alpha-1-Antitrypsin [LAB927]
Amikacin Drug Level [LAB555]
Beta-2-Microglobulin [LAB49]
Bile Acids, Total [LAB2713]
C3 Complement [LAB152]
C4 Complement [LAB151]
Carbamazepine Drug Level [LAB22]
Ceruloplasmin [LAB582]
Drug of Abuse – urine screens [LAB500 and LAB1032]
Ethylene Glycol, Plasma (by immunoassay) [LAB7453]
Everolimus Drug Level [LAB7456]
Haptoglobin [LAB89]
Homocysteine [LAB93]
Immunoglobulin A (IgA) [LAB73]
Immunoglobulin G (IgG) [LAB71]
Immunoglobulin M (IgM) [LAB72]
Keppra (Levetiracetam) Drug Level [LAB477]
Lamotrigine (Lamictal) Drug Level (LAB475]
Lidocaine Drug Level [LAB641]
Methotrexate Drug Level [LAB481]
Nicotine Metabolite, Rapid Screen [LAB8071]
Pentobarbital Drug Level [LAB656]
Phenobarbital Drug Level [LAB30]
Phenytoin Free Drug Level [LAB32]
Rheumatoid Factor [LAB206]
THC Urine Screen [LAB5203]
THC Urine Screen with Reflexed Confirmation [LAB7388]
Theophylline Drug Level [LAB35]
Tobramycin Drug Level [LAB36]
Valproic Acid Drug Level [LAB25]

Questions should be directed to Matthew Krasowski, MD, PhD, medical director of the Clinical Chemistry Laboratory (384-9380,